Skip to main content
HLB Therapeutics Co.,Ltd. logo

HLB Therapeutics Co.,Ltd. — Investor Relations & Filings

Ticker · 115450 ISIN · KR7115450009 KO Manufacturing
Filings indexed 444 across all filing types
Latest filing 2023-12-26 Notice of Dividend Amou…
Country KR South Korea
Listing KO 115450

About HLB Therapeutics Co.,Ltd.

https://hlbtherapeutics.co.kr/en/

HLB Therapeutics Co., Ltd. is a biopharmaceutical company specializing in the development of innovative, first-in-class drugs for rare and intractable diseases. The company's clinical-stage pipeline focuses on addressing unmet medical needs in ophthalmology and oncology. Key development programs include RGN-259, a therapeutic agent for Dry Eye Disease and Neurotrophic Keratopathy, and OKN-007 for the treatment of Glioblastoma Multiforme. Additionally, the company is advancing a Natural Killer (NK) cell therapy through late-stage clinical trials to provide new therapeutic options for patients.

Recent filings

Filing Released Lang Actions
[기재정정]주식배당결정
Notice of Dividend Amount Classification · 100% confidence The document is a regulatory filing from HLB Therapeutics regarding a 'Stock Dividend Decision' (주식배당결정). It details a correction (정정신고) to a previous dividend announcement due to changes in the total number of issued shares resulting from the conversion of convertible bonds. Since the document specifically announces the details of a dividend distribution (amount, record date, and related share count adjustments), it falls under the category of dividend announcements.
2023-12-26 Korean
[기재정정]주식배당결정
Notice of Dividend Amount Classification · 100% confidence The document is a regulatory filing from HLB Therapeutics regarding a 'Stock Dividend Decision' (주식배당결정). It details a correction to a previous filing concerning the number of shares to be issued as dividends and the total number of shares outstanding. Since this document specifically announces the details of a dividend distribution (amount, record date, and related adjustments), it falls under the category of dividend announcements.
2023-12-26 Korean
배당락(주식배당)
Notice of Dividend Amount Classification · 100% confidence The document is a short notice regarding '배당락' (ex-dividend date) for HLB Therapeutics. It specifies the ex-dividend date, the reason (stock dividend), and the reference price. This falls under the category of dividend-related announcements.
2023-12-26 Korean
주식배당결정
Notice of Dividend Amount Classification · 100% confidence The document is a formal announcement regarding a 'Stock Dividend Decision' (주식배당결정) by HLB Therapeutics. It details the number of shares per dividend, the total number of shares to be issued, the record date, and the board resolution date. This falls under the category of dividend announcements, which is specifically covered by the 'Notice of Dividend Amount' (DIV) category.
2023-12-20 Korean
전환가액의조정(제15회차)
Share Issue/Capital Change Classification · 100% confidence The document is a formal regulatory filing regarding the adjustment of the conversion price for convertible bonds (15th series) issued by HLB Therapeutics. It details the calculation method, the change in conversion price, and the impact on the number of convertible shares. This type of disclosure is a standard corporate action related to capital structure and financing instruments, which falls under the 'Capital/Financing Update' category.
2023-12-18 Korean
주주명부폐쇄기간또는기준일설정
Regulatory Filings Classification · 95% confidence The document is a short regulatory announcement regarding the setting of a record date and shareholder register closure for an upcoming Annual General Meeting. It does not contain the full meeting materials or proxy statements, but rather serves as a formal notice of the administrative procedure for determining shareholder eligibility. Given its nature as a regulatory notification of a corporate event, it fits best under the RNS category.
2023-12-15 Korean

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.